Literature DB >> 1951242

Haptoglobin prevents renal dysfunction associated with intravariceal infusion of ethanolamine oleate.

H Miyoshi1, S Ohshiba, A Matsumoto, K Takada, E Umegaki, I Hirata.   

Abstract

Endoscopic injection sclerotherapy (EIS) with ethanolamine oleate was performed in patients with esophageal varices either with (18 patients) or without (19 patients) pretreatment with haptoglobin. The serum levels of urea nitrogen, creatinine, and beta 2-microglobulin, the creatinine clearance, and the urinary levels of N-acetyl-beta-D-glucosaminidase and urinary beta 2-microglobulin were measured before and after EIS. Indices of the glomerular filtration rate (serum levels of urea nitrogen, creatinine, beta 2-microglobulin; creatinine clearance) showed no significant changes after EIS in either the haptoglobin-treated or untreated groups. However, the increase in the urinary parameters after EIS (which are indices of renal tubular function) was suppressed in the haptoglobin-treated group (p less than 0.005 for urinary beta 2-microglobulin). Our results indicated that the administration of haptoglobin has a prophylactic effect on renal tubular dysfunction associated with the use of ethanolamine oleate in EIS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1951242

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Ruptured high flow gastric varices with an intratumoral arterioportal shunt treated with balloon-occluded retrograde transvenous obliteration during temporary balloon occlusion of a hepatic artery.

Authors:  Motoki Nakai; Morio Sato; Hirohiko Tanihata; Tetsuo Sonomura; Shinya Sahara; Nobuyuki Kawai; Masashi Kimura; Masaki Terada
Journal:  World J Gastroenterol       Date:  2006-09-07       Impact factor: 5.742

Review 2.  Balloon-occluded retrograde transvenous obliteration of varices: focusing on the portal hemodynamics and the recent techniques.

Authors:  Shozo Hirota; Kaoru Kobayashi; Yasukazu Kako; Haruyuki Takaki; Koichiro Yamakado
Journal:  Hepatol Int       Date:  2017-09-05       Impact factor: 6.047

3.  Foam sclerotherapy using polidocanol for balloon-occluded retrograde transvenous obliteration (BRTO).

Authors:  Sun Young Choi; Jong Yun Won; Kyung Ah Kim; Do Yun Lee; Kwang-Hun Lee
Journal:  Eur Radiol       Date:  2010-08-26       Impact factor: 5.315

4.  Three benefits of microcatheters for retrograde transvenous obliteration of gastric varices.

Authors:  Tetsuo Sonomura; Wataru Ono; Morio Sato; Shinya Sahara; Kouhei Nakata; Hiroki Sanda; Nobuyuki Kawai; Hiroki Minamiguchi; Motoki Nakai; Kazushi Kishi
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

5.  Percutaneous transhepatic obliteration-related procedures for isolated gastric varices: experience of three cases.

Authors:  Suguru Hirose; Naoyuki Hasegawa; Kensaku Mori; Masato Endo; Masahiko Terasaki; Kazunori Ishige; Kuniaki Fukuda; Yuji Mizokami; Kiichiro Tsuchiya
Journal:  Clin J Gastroenterol       Date:  2021-11-11

6.  Emergency balloon-occluded retrograde transvenous obliteration of ruptured gastric varices.

Authors:  Tetsuo Sonomura; Wataru Ono; Morio Sato; Shinya Sahara; Kouhei Nakata; Hiroki Sanda; Nobuyuki Kawai; Hiroki Minamiguchi; Motoki Nakai; Kazushi Kishi
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

7.  Utility of low-dose gelatin sponge particles and 5% ethanolamine oleate iopamidol mixture in retrograde transvenous obliteration (GERTO) for gastric varices.

Authors:  Atsushi Jogo; Akira Yamamoto; Toshio Kaminoh; Mariko Nakano; Ken Kageyama; Etsuji Sohgawa; Shinichi Hamamoto; Yukimasa Sakai; Masao Hamuro; Norifumi Nishida; Yukio Miki
Journal:  Br J Radiol       Date:  2020-02-14       Impact factor: 3.039

8.  Successful treatment of ruptured duodenal varices with dual balloon-occluded embolotherapy.

Authors:  Osamu Ikeda; Yutaka Nakasone; Toru Beppu; Hideo Baba; Yasuyuki Yamashita
Journal:  Acta Radiol Short Rep       Date:  2012-02-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.